We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$80.8M
Cap. Flow
+$24.5M
Cap. Flow %
2.53%
Top 10 Hldgs %
34.67%
Holding
117
New
17
Increased
44
Reduced
27
Closed
27

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$19.2M
3
NVST icon
Envista
NVST
+$18.5M
4
SYK icon
Stryker
SYK
+$17.7M
5
ABBV icon
AbbVie
ABBV
+$16.6M

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$26M
2
TERN
Terns Pharmaceuticals
TERN
+$25.1M
3
FOLD
Amicus Therapeutics
FOLD
+$21.2M
4
MCK icon
McKesson
MCK
+$21.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$4.83B
$12.5M 1.29%
259,184
-406,024
-61% -$18M
ASMB icon
27
Assembly Biosciences
ASMB
$506M
$11.4M 1.18%
411,227
+161,870
+65% +$4.62M
GPCR icon
28
Structure Therapeutics
GPCR
$3.49B
$11.2M 1.15%
232,093
+177,093
+322% +$12.1M
MCK icon
29
McKesson
MCK
$98.5B
$11M 1.13%
12,676
-23,679
-65% -$21.1M
STOK icon
30
Stoke Therapeutics
STOK
$1.82B
$11M 1.13%
336,519
-93,636
-22% -$3.07M
VRDN icon
31
Viridian Therapeutics
VRDN
$2.13B
$10.9M 1.13%
557,936
-230,140
-29% -$6.84M
WAY
32
Waystar Holding Corp
WAY
$4.32B
$10.7M 1.1%
443,058
+74,035
+20% +$1.96M
MLYS icon
33
Mineralys Therapeutics
MLYS
$2.35B
$10.3M 1.06%
380,137
-30,112
-7% -$883K
EWTX icon
34
Edgewise Therapeutics
EWTX
$4.39B
$10.2M 1.05%
322,828
-104,862
-25% -$3.02M
XERS icon
35
Xeris Biopharma Holdings
XERS
$1.44B
$9.98M 1.03%
1,721,264
+29,679
+2% +$197K
THC icon
36
Tenet Healthcare
THC
$20.1B
$9.46M 0.98%
50,123
-10,391
-17% -$2.19M
AORT icon
37
Artivion
AORT
$1.23B
$9.23M 0.95%
252,014
+33,345
+15% +$1.32M
NUVL
38
DELISTED
Nuvalent
NUVL
$9.02M 0.93%
88,078
-30,634
-26% -$3.12M
ATEC icon
39
Alphatec Holdings
ATEC
$1.27B
$8.96M 0.92%
823,763
+546,582
+197% +$7.96M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$36.3B
$8.91M 0.92%
26,916
-20,787
-44% -$7.07M
AXGN icon
41
Axogen
AXGN
$2.1B
$8.88M 0.92%
268,160
+17,842
+7% +$580K
IMNM icon
42
Immunome
IMNM
$2.52B
$8.82M 0.91%
403,487
+125,675
+45% +$2.8M
AMLX icon
43
Amylyx Pharmaceuticals
AMLX
$2.05B
$8.64M 0.89%
621,458
+239,698
+63% +$3.37M
IDXX icon
44
Idexx Laboratories
IDXX
$42.9B
$8.43M 0.87%
+15,000
New +$9.62M
WAT icon
45
Waters Corp
WAT
$36.8B
$7.88M 0.81%
26,447
-15,452
-37% -$5.29M
ADPT icon
46
Adaptive Biotechnologies
ADPT
$3.56B
$7.66M 0.79%
551,815
+150,085
+37% +$2.39M
UPB
47
Upstream Bio Inc
UPB
$349M
$7.08M 0.73%
786,783
-47,776
-6% -$860K
ERAS icon
48
Erasca
ERAS
$6.63B
$6.58M 0.68%
+406,702
New +$4.81M
APGE icon
49
Apogee Therapeutics
APGE
$10.2B
$6.54M 0.67%
77,686
-52,383
-40% -$3.8M
COO icon
50
Cooper Companies
COO
$13.7B
$6.43M 0.66%
89,883
-35,452
-28% -$2.8M
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GLR
Great Lakes Retirement Sandusky, Ohio $967M AUM 25.11% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Parkman Healthcare Partners held 117 positions worth $970M, down 7.7% from $1.05B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners's Q1 2026 filing shows 17 new, 44 increased, 27 reduced and 27 closed positions. Its largest new stake was Eli Lilly: 34,616 shares worth $31.8M. The largest sale was Masimo, an estimated $26M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q1 2026 buy was Eli Lilly: 34,616 shares worth $31.8M.
  • Parkman Healthcare Partners added most to PTC Therapeutics in Q1 2026, an estimated $19.2M increase.
  • Parkman Healthcare Partners's biggest Q1 2026 reduction was McKesson, cutting an estimated $21.1M.
  • Parkman Healthcare Partners fully exited Masimo in Q1 2026, selling an estimated $26M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $970M portfolio in Q1 2026.
  • Parkman Healthcare Partners opened 17 new positions and closed 27 in Q1 2026.
  • Parkman Healthcare Partners's portfolio value fell 7.7% quarter-over-quarter to $970M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.